# Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®

> **NCT01187550** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 214 (actual)

## Conditions studied

- Dwarfism, Pituitary

## Interventions

- **DRUG:** Recombinant human growth hormone (r-hGH)

## Key facts

- **NCT ID:** NCT01187550
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-09
- **Final completion:** 2009-04
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2014-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01187550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01187550, "Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01187550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*